Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005

Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 – present)

Published:2014-12 Issue:1 Volume:25 Page:69-90
ISSN:1354-3776
Container-title:Expert Opinion on Therapeutic Patents
language:en
Short-container-title:Expert Opinion on Therapeutic Patents

Author:

Celanire Sylvain¹,Sebhat Iyassu²,Wichmann Juergen³,Mayer Stanislas⁴,Schann Stephan⁵,Gatti Silvia⁶

Affiliation:

1. 1CEO, Pragma Therapeutics, 9 rue Ada Byron, Domaine de Chosal, Archamp Technopole, 74166 Saint-Julien-en-Genevois Cedex, France ;

2. 2Merck Research Laboratories, Chemistry, Merck & Co., Inc., 2015 Galloping Hill Road, Kenilworth, NJ 07033, USA

3. 3Roche Innovation Center Basel, Roche Pharmaceutical Research and Early Development, Medicinal Chemistry, Bldg. 092/6.56C, Grenzacherstrasse 124, CH-4070 Basel, Switzerland

4. 5Domain Therapeutics, BioParc, 850 Bld Sébastien Brant 67400 Illkirch, France

5. 6Domain Therapeutics, BioParc, 850 Bld Sébastien Brant 67400 Illkirch, France

6. 4Roche Innovation Center Basel, Roche Pharmaceutical Research and Early Development, NORD Neuroscience, Bldg. 068/23a, Grenzacherstrasse 124, CH-4070 Basel, Switzerland

Publisher

Informa Healthcare

Subject

Drug Discovery,Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1517/13543776.2014.983899

Reference61 articles.

1. Metabotropic Glutamate Receptors: Physiology, Pharmacology, and Disease

2. Group II metabotropic glutamate receptor agonists and positive allosteric modulators as novel treatments for schizophrenia

3. mGluR2 positive allosteric modulators: a patent review (2009 – present)

4. Use of metabotropic glutamate 5-receptor antagonists for treatment of levodopa-induced dyskinesias

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. BCI-838, an orally active mGluR2/3 receptor antagonist pro-drug, rescues learning behavior deficits in the PS19 MAPT mouse model of tauopathy;Neuroscience Letters;2023-02

2. Targeting mGluR2/3 for treatment of neurodegenerative and neuropsychiatric diseases;Pharmacology & Therapeutics;2022-11

3. Input-specific regulation of glutamatergic synaptic transmission in the medial prefrontal cortex by mGlu 2 /mGlu 4 receptor heterodimers;Science Signaling;2021-04-06

4. Negative allosteric modulators of group II metabotropic glutamate receptors: A patent review (2015 – present);Expert Opinion on Therapeutic Patents;2021-03-31

5. Negative allosteric modulators of metabotropic glutamate receptor 3 target the stem-like phenotype of glioblastoma;Molecular Therapy - Oncolytics;2021-03